中医药早期介入新型冠状病毒肺炎的多中心、回顾性队列研究  

Retrospective multi-center cohort study of traditional Chinese medicine early intervention in Corona Virus Disease 2019

作　　者：苏芮 张复春[2] 陈晓蓉[3] 李秀惠[4] 田霞[5] 邱荣仙[6] 李继科 李薇 林路平[2] 陆云飞[3] 朱俊腾[6] 王烁 刘清泉[1] SU Rui;ZHANG Fu-chun;CHEN Xiao-rong;LI Xiu-hui;TIAN Xia;QIU Rong-xian;LI Ji-ke;LI Wei;LIN Lu-ping;LU Yun-fei;ZHU Jun-teng;WANG Shuo;LIU Qing-quan(Infectious Diseases Department,Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Department of Chinese Medicine,Eighth People's Hospital,Guangzhou 510060,China;Department of Traditional Chinese Medicine,Shanghai Public Health Clinical Center,Shanghai 201500,China;Department of Chinese Medicine,Bejing You'an Hospital,Capital Medical University,Beijing 100069,China;Department of Traditional Chinese Medicine,Shenyang Sixth People's Hospital,Shenyang 110000,China;Department of Chinese Medicine,Affliated Hospital,Putian Medical Research,Putian 351100,China;Department of Traditional Chinese Medicine,Chengdu Public Health Clinical Center,Chengdu 610000,China;Department of Traditional Chinese Medicine,Dalian Sixth People's Hospital,Dalian 116000,China)

机构地区：[1]首都医科大学附属北京中医医院感染性疾病科,北京100010 [2]广州市第八人民医院中医科,广州510060 [3]上海市公共卫生临床中心中医科,上海201500 [4]首都医科大学附属北京佑安医院中医科,北京100069 [5]沈阳市第六人民医院中医科,沈阳110000 [6]莆田学院附属医院中医科,莆田351100 [7]成都市公共卫生临床中心中医科,成都610000 [8]大连市第六人民医院中医科,大连116000

出　　处：《中华中医药杂志》2022年第12期7475-7481,共7页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家科技重大专项(No.2017ZX1030501);国家重点研发计划(No.2021YFC1712901);国家中医药管理局创新团队项目(No.ZYYCXTD-D-202201)。

摘　　要：目的:通过大样本多中心回顾性队列研究,明确中医药早期治疗新型冠状病毒肺炎(COVID-19)的优势。方法:回顾分析8省市COVID-19定点收治医院收治的COVID-19全部连续病例。按照患者使用中药时间分为入院1 d内服用中药组、入院1~3 d服用中药组、3 d后服用中药组以及西药组,分析各组主要与次要结局指标差异。结果:各组在住院时间,核酸转阴时间,咳痰、气促、乏力、腹痛、腹泻5个主要症状缓解时间,ICU收治时间及激素使用时间等方面具有显著性差异(P<0.05)。其中,入院1~3 d服用中药组与西药组比较核酸转阴时间具有显著性差异(P<0.01)。入院1~3 d服用中药组ICU收治时间显著低于西药组(P<0.05)。结论:中医药早期治疗在缩短住院时间、核酸转阴时间、主要症状缓解时间、ICU收治时间、激素使用时间等方面具有一定优势。Objective:To clarify the advantages of early use of traditional Chinese medicine(TCM)in Corona Virus Disease 2019(COVID-19)treatment and prevention,by a retrospective multi-center cohort study.Methods:All continuous COVID-19 cases of designated hospitals from the 8 provincial and cities.According to different period of TCM using,patients were divided in to TCM≤1 d,TCM>1 and≤3 d,TCM>3 d and Western medicine group,and the main outcomes were analyzed.Results:There were significant differences in the time of hospitalization,viral shedding duration,relieving time of the five main symptoms of expectoration,shortness of breath,fatigue,abdominal pain and diarrhea,ICU length of stay and duration of corticosteroids among the groups(P<0.05).Among them,there were significant differences in viral shedding duration(P<0.01)and ICU length of stay(P<0.05)between TCM>1 and≤3 d group and Western medicine group.Conclusion:TCM early treatment has certain advantages in shortening hospital length of stay,viral shedding duration,main symptom relief time,ICU length of stay,anddurationofcorticosteroids.

关 键 词：新型冠状病毒肺炎 中医药 早期治疗 回顾性 队列 多中心 

分 类 号：R259[医药卫生—中西医结合]